Search clinical trials for: Pulmozyme (dornase alfa)

Total 3095 results

Ultragenyx Pharmaceutical Inc

Completed

Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

Mucopolysaccharidosis | Sly Syndrome | Mucopolysaccharidosis VII | MPS VII

Spain, United States, Portugal
Hoffmann-La Roche

Completed

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China, Hong Kong, Taiwan, Singapore, Korea, Republic of, New Zealand, Thailand, Brazil, Russian Federation, Australia
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Chronic Hepatitis B

China
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
AstraZeneca
LOGEX Healthcare Analytics Amsterdam The Netherlands

Recruiting

Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya

Hemorrhage

Netherlands
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
Genentech, Inc.

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis

Germany, Italy, Poland, Russian Federation, Serbia, United States, Ukraine, Bulgaria, Georgia, Greece, Ireland, Moldova, Republic of, Spain, United Kingdom
Novo Nordisk A/S

Completed

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

Congenital Bleeding Disorder | Haemophilia A

Japan
Shire

Completed

Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease

Gaucher Disease

Japan
Federal Research Institute of Pediatric Hematology...

Completed

TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID

Primary Immune Deficiency Disorder | Hematopoietic Stem Cell Transplantation

Russian Federation
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (guardian™ 5)

Congenital Bleeding Disorder | Haemophilia A

Italy, Sweden, Netherlands, Austria, Spain, United States, Switzerland, Germany, France, Hungary, Greece, Slovenia, Czechia, Slovakia, Poland
Pfizer

Completed

A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Gaucher Disease

Israel, Paraguay, South Africa
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects (guardian™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Japan, Denmark, Hungary, Israel, Turkey, Russian Federation, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

Congenital Bleeding Disorder | Haemophilia A

United Kingdom, Malaysia
Genzyme, a Sanofi Company

Completed

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Glycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)

United States, Netherlands, United Kingdom, Germany
Genzyme, a Sanofi Company

Completed

High Dose or High Dose Frequency Study of Alglucosidase Alfa

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase Deficiency

United States, Canada, Australia
Australian and New Zealand Intensive Care Research...
Monash University; University College Dublin; Health Research Board, Ireland; Health... and other collaborators

Recruiting

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)

Wounds and Injuries | Trauma | Traumatic Brain Injury | Multiple Trauma | Major Trauma | Traumatic Injury | Penetrating Injury | Blunt Injury

Australia, Ireland, Finland, New Zealand, Slovenia, Germany, Saudi Arabia, Switzerland
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Anaemia

Korea, Republic of, Russian Federation, Spain, United States, Australia, United Kingdom, Brazil, Italy, Argentina, Poland, Romania, France, Canada
Andrea L Woodland

Completed

Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients

Anemia | Chronic Kidney Disease
University of Florida
Ortho Biotech Clinical Affairs, L.L.C.

Completed

Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer

Anemia

United States
Dr. Sami Ulus Children's Hospital

Completed

Perfusion Index Variability in Respiratory Distress Syndrome

Poor Peripheral Perfusion
Beijing Ditan Hospital

Unknown

The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Merck Sharp & Dohme LLC

Completed

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

Chronic Hepatitis C | Liver Fibrosis
Hoffmann-La Roche

Completed

An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B

Hepatitis B, Chronic

Morocco
Hoffmann-La Roche

Completed

PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

France, Sweden, Austria, Hungary, Poland, Romania, Slovenia, Croatia, Serbia, Canada, Brazil, Morocco, Mexico, Macedonia, The Former Yugoslav Republic of
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

Antiviral Treatment of Chronic Hepatitis B
Eli Lilly and Company

Completed

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Severe Sepsis

United States, Belgium, Spain, France, Finland, Germany, Canada, United Kingdom, Puerto Rico
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Hoffmann-La Roche

Completed

A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

Healthy Volunteers

New Zealand, Taiwan, Australia, Hong Kong, Singapore
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (Pyrenees)

Anemia | End Stage Renal Disease (ESRD)

Bulgaria, Croatia, Czechia, Germany, Hungary, Poland, Russian Federation, Serbia, Spain, United Kingdom, Belgium, France, Georgia, Italy, Portugal, Romania, Slovakia
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Bintrafusp Alfa Program Rollover Study

Cancer | Lung Cancer

Korea, Republic of, Spain, Germany, Japan, Taiwan, China, Italy, United States, Belgium, Russian Federation, Turkey, Ukraine
Novo Nordisk A/S

Completed

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities (THIRd)

Haemophilia A

Italy
Biohaven Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT)

Neuromuscular Diseases | Spinal Muscular Atrophy | SMA

United States, Netherlands, United Kingdom, Spain, Czechia, Belgium, Germany, Italy, Poland
EMD Serono Research & Development Institute, Inc.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Terminated

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

United States, France, Belgium, Spain, Russian Federation, Italy
Novo Nordisk A/S

Completed

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Congenital Bleeding Disorder | Haemophilia A

Mexico
Novo Nordisk A/S

Terminated

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

Haemophilia A

Austria, Serbia, Bulgaria, United Kingdom, Germany, France, Turkey
Novo Nordisk A/S

Completed

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period (guardian 10)

Congenital Bleeding Disorder | Haemophilia A

India
Novo Nordisk A/S

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (guardian ™9)

Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Completed

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen (TelapreVIH)

HIV Infection | Hepatitis C, Chronic

France
Fundación GECP

Recruiting

Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES)

Mesothelioma; Lung

Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Uterine Cervical Neoplasms

Korea, Republic of, United States, France, Belgium, China, Argentina, Spain, Australia, Russian Federation, Brazil, Hungary, Japan
AM-Pharma

Terminated

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

Acute Kidney Injury Due to Sepsis

Belgium, Spain, United States, Austria, Denmark, France, United Kingdom, Finland, New Zealand, Australia, Germany, Canada, Netherlands, Ireland, Japan
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Pfizer

Completed

A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Gaucher Disease

Israel, South Africa, Paraguay
National Institute of Diabetes and Digestive and...

Not yet recruiting

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Chronic Hepatitis B

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Alios Biopharma Inc.

Withdrawn

A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

Hepatitis B, Chronic
Yao Xie

Unknown

The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China

Search clinical trials for: Pulmozyme (dornase alfa)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations